Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Direvo Biotech AG

Latest From Direvo Biotech AG

Recent Financings Boost Biotech M&A Returns

A recent influx of venture capital does appear to place start-ups in an optimal position to negotiate better terms and receive a higher payment.

BioPharmaceutical Business Strategies

Mind over matter - partnerships: CNS deals signed over the past five years

Attention deficit hyperactivity disorder (ADHD)







Deal terms


March 2009






co-promotion of Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of attention deficit hyperactivity disorder in the US


November 2008




Paladin Labs


three-year contract giving Paladin exclusive distribution rights for GSK's Dexedrine (dextroamphetamine sulfate) for the treatment of ADHD and in the adjunctive treatment of narcolepsy, in Canada

Neurology Mexico

Bayer rules out expensive acquisitions to focus on academia

Bayer is adamant that it will avoid billion-dollar transactions in healthcare this year and has no interest in buying a generics business. Instead it will focus on developing external links with research institutions such as universities, says board chairman Werner Wenning.

Cancer Companies

Reacting to the Crisis: Biotech Venture Capital's Plan B

There are significant dilemmas facing life sciences venture capitalists buffeted by the simultaneous but distinct insults of global financial calamity and trickier-than-ever biotech partnering, regulatory, and reimbursement environments. Venture's best bet at a return is an uptick in decidedly un-venture PIPE deals that take advantage of public biotechs' miserable valuations, but those deals aren't exactly growing on trees. Despite the surfeit of bad news, there may be a bright side.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies